A Phase 2/3 interventional study of Continuous Positive Airway Pressure and Tirzepatide in Sleep Apnoea, Obesity & Overweight and Sleep Apnea Syndrome, Obstructive, sponsored by Woolcock Institute of Medical Research. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Woolcock Institute of Medical Research · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Sleep Apnea, Obstructive with a site in Australia — 16 open to participants now, 19 under way, 6 of them phase 3. Sleep Apnea, Obstructive · Australia.
Among the 62 studies in Sleep Apnea, Obstructive with a site in Australia, this one is the 13th largest by planned enrollment of the 57 interventional ones that give a count, is one of 6 that started in 2026, is the only one in phase 2/3, reaches primary completion later than 17 of the 18 other live ones, and was the 62nd registered.
2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.
Browse Sleep Apnea, Obstructive studies →16 of the 62 studies in Sleep Apnea, Obstructive with a site in Australia are open now. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Australia, United States, China and 7 more countries
Ages 18+
Novo Nordisk A/S · Sites in Australia, United States, China and 7 more countries
Ages 18+
Eli Lilly and Company · Sites in Australia, United States, Brazil and 8 more countries
Ages 18+
Restera, Inc. · Sites in Australia
Ages 18+
Flinders University · Sites in Australia
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 313 Sleep Apnea, Obstructive studies recruiting now, 146 (47%) set no upper age limit and 124 (40%) stop at 75 or younger; 52 take children under 18; 65 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 13 · Phase 4 1
First in 2004; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 256 is above the median of 52 across 1,474 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 42 across the 57 interventional studies, 90 across the 5 observational. Of the 38 that completed or were terminated, 6 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 62 have an industry lead sponsor. The 10 most frequent:
Woolcock Institute of Medical Research is the lead sponsor of 17 studies on the registry; 12 are open to participants now.
Woolcock Institute of Medical Research has 3 studies filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
8 of the studies in Sleep Apnea, Obstructive with a site in Australia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
| NCT07049744XII MedicalHypoglossal Nerve Stimulation for the Treatment of Adult Obstructive Sleep Apnea | 2026-12 |
| NCT07400861ResMedStudy of Min-Max APAP Recommender Tool | 2026-12-01 |
| NCT06930404ResMedData Collection Study to Review Novel Methods for Diagnosing Obstructive Sleep Apnea | 2026-12-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 62 studies in Sleep Apnea, Obstructive with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
When used, continuous positive airway pressure (CPAP) is an effective treatment for obstructive sleep apnea (OSA), a condition that is mainly caused by overweight and obesity. However, CPAP is plagued by poor adherence and high rates of discontinued use leaving most patients undertreated and at risk of serious health complications. This study aims to test whether new effective weight loss pharmacotherapy is superior to CPAP for alleviating OSA and improving health outcomes.
The TIRZE-PAP study is a parallel randomised superiority trial comparing weight loss with weekly tirzepatide (15mg or the maximum tolerated dose) versus CPAP, in 256 people with moderate-severe OSA (AHI≥15/hr) and overweight or obesity (BMI: ≥27kg/m2). Participants allocated to CPAP will receive therapy as per usual care by their treating physician. Participants allocated to tirzepatide will undergo a 20-week stepped titration with a monthly increase of dose to a maximum 15mg (or maximum tolerated) by week 20. Outcomes will be collected over two 28-day periods commencing at baseline (pre-intervention weeks -4 to 0) and at follow-up (post-intervention weeks 48 to 52).
2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.
This study's planned enrollment of 256 is above the median of 52 across 1,474 interventional studies indexed under Sleep Apnea, Obstructive.
Browse Sleep Apnea, Obstructive studies →Woolcock Institute of Medical Research is the lead sponsor of 17 studies on the registry; 12 are open to participants now.
Compared within Sleep Apnea, Obstructive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sleep Apnea Syndromes. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
OSA or other respiratory related criteria:
Glycaemia related criteria:
Obesity related criteria:
Other criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Continuous Positive Airway Pressure
Drug: Tirzepatide
CPAP will be set at a fixed pressure that abolishes apnoeas and hypopneas determined from an in-lab titration study or set according to a pre-determined algorithm using an auto-titrating machine at home. Participants may also be counselled on losing weight with diet and exercise as per usual practice.
Patients allocated to weight loss with tirzepatide will be managed by the study dietitian. The tirzepatide formulation is administered subcutaneously once weekly using single-use injection pens. Participants will undergo a 20-week dose escalation phase (starting at 2.5mg/week for 4 weeks, 5 mg/week for 4 weeks, 7.5mg/week for 4 weeks, 10mg/week for 4 weeks, 12.5mg/week for 4 weeks) followed by a dose maintenance phase of 15mg/week for the remainder of the 12-month study period. Participants unable to tolerate the next highest dose will be maintained on the maximum tolerable dose for the duration of the intervention.
Breathing Disturbance Index (BDI)
BDI is the primary severity metric of OSA in the trial which is measured by the number of breathing disturbances per hour of sleep. This is measured using contactless mattress-based OSA monitors (SleepTracker-AI) that can automatically and reliably measure true OSA alleviation every night for the entire period of sleep.
Time frame: The mean BDI measured over 28 nights of monitoring is calculated for baseline (Weeks -4 to 0) and follow-up (Weeks 48 to 52)
Hypoxia - Oxygen Desaturation Index (ODI 3%)
ODI 3% is calculated as the number of oxygen desaturation events ≥3% per hour as a percentage of time in bed, estimated using at-home oximetry (RingConn Gen 2).
Time frame: ODI 3% will be determined as a mean of 7-10 nights of data acquired at baseline and a mean of 7-10 nights of data acquired at 12month follow-up.
Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment Short Form 8a Score
The Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment Short Form 8a Score is used to assess participant-reported levels of alertness, sleepiness, and tiredness and the functional impairments associated with sleep problems or reduced alertness over the past 7 days. Impairment ranges from a minimum of 5 (no impairment) to a maximum of 40 (maximal impairment).
Time frame: Collected at Baseline and 3,6,9 and 12 months.
Epworth Sleepiness Scale (ESS)
The Epworth Sleepiness Scale (ESS) measures self-reported subjective sleepiness using an 8-item questionnaire. Sleepiness ranges from a minimum of 0 (no sleepiness) to a maximum of 24 (severe sleepiness).
Time frame: Collected at Baseline and 3,6,9 and 12 months.
Ambulatory Blood Pressure - Sleep Systolic Blood Pressure (SBP)
Sleep SBP is measured hourly, using an ambulatory blood pressure monitor, for a self-reported sleep period.
Time frame: Baseline and Week 52
Cardiometabolic Fasted Blood Markers - Low-Density Lipoproteins (LDL)
Low-density lipoproteins are measured from fasted venous blood.
Time frame: Screening and Week 52
Cardiometabolic Fasted Blood Markers - HbA1c
HbA1c, or glycated haemoglobin, assesses long-term glycaemic control. It is measured from fasted venous blood.
Time frame: Screening and Week 52
Hypoxic Burden
This is an oximetry-derived measurement using established algorithms. Hypoxic burden measures are quantified from nightly at-home oximetry acquired using an oximeter device (RingConn Gen 2).
Time frame: The mean nightly hypoxic burden measured over 7-10 nights of monitoring is calculated for baseline and 12 month follow-up.
Short Form Functional Outcomes of Sleep Questionnaire (FOSQ-10)
The Short Form Functional Outcomes of Sleep Questionnaire (FOSQ-10) is used to assess the impact of sleep disorders/excessive sleepiness on daily functioning. Function ranges from a minimum of 4 (low function) to a maximum of 20 (good function).
Time frame: Baseline and 3, 6, 9 and 12 months.
Cardiometabolic Fasted Blood Markers - Glucose
Glucose is measured from fasted venous blood.
Time frame: Screening and Week 52
Cardiometabolic Fasted Blood Markers - Triglycerides [TAG]
Triglycerides are measured from fasted venous blood.
Time frame: Screening and Week 52
Cardiometabolic Fasted Blood Markers - High-Density Lipoproteins (HDL)
High-density lipoproteins are measured from fasted venous blood.
Time frame: Screening and Week 52
Cardiometabolic Fasted Blood Markers - Total Cholesterol
Total cholesterol is measured from fasted venous blood.
Time frame: Screening and Week 52
Ambulatory Blood Pressure - Sleep Diastolic Blood Pressure (DBP)
Sleep DBP is measured hourly over 24 hours using an ambulatory blood pressure monitor, segmented for a self-reported sleep period.
Time frame: Baseline and Week 52
Ambulatory Blood Pressure - Wake Systolic Blood Pressure (SBP)
Wake SBP is measured hourly over 24 hours using an ambulatory blood pressure monitor, segmented for a self-reported wake period.
Time frame: Baseline and Week 52
Ambulatory Blood Pressure - Wake Diastolic Blood Pressure (DBP)
Wake DBP is measured hourly over 24 hours using an ambulatory blood pressure monitor, segmented for a self-reported wake period.
Time frame: Baseline and Week 52
Ambulatory Blood Pressure - 24-hour Mean Arterial Pressure (MAP)
24-hour MAP is calculated hourly over 24 hours using an ambulatory blood pressure monitor. MAP = DBP + (SBP - DBP)/3
Time frame: Baseline and Week 52
Office Blood Pressure - Systolic Blood Pressure (SBP)
SBP is measured using an automated blood pressure machine after sitting quietly for 5 minutes.
Time frame: Baseline and Week 52
Office Blood Pressure - Diastolic Blood Pressure (DBP)
DBP is measured using an automated blood pressure machine after sitting quietly for 5 minutes.
Time frame: Baseline and Week 52
Anthropometry - Body Mass Index (kg/m^2)
BMI is calculated as weight in kilograms, divided by height measured in metres squared.
Time frame: Baseline and Week 52
Anthropometry - Weight (kg)
Weight is measured in kilograms.
Time frame: Baseline and Week 52
Anthropometry - Body Weight (% change)
Change in Weight is calculated as a percentage of change from baseline to 52-weeks.
Time frame: Baseline and Week 52
Anthropometry - Waist Circumference
Waist circumference is measured in centimetres, using a tape measure positioned in line with the superior iliac crest of the hip.
Time frame: Baseline and Week 52
Anthropometry - Neck Circumference
Neck circumference is measured in centimetres, using a tape measure positioned inferior to the laryngeal prominence.
Time frame: Baseline and Week 52
CAmbridge Neuropsychological Test Automated Battery (CANTAB) Multitasking Test
The Multitasking Test is used to assess executive functioning and cued attentional set shifting.
Time frame: Baseline and Week 52
CANTAB Spatial Working Memory Task
The Spatial Working Memory Task is used to assess working memory and strategy and is applicable in the assessment of general cognitive function.
Time frame: Baseline and Week 52
Psychomotor Vigilance Task (PVT)
The PVT is used to assess a participant's level of alertness.
Time frame: Baseline and Week 52
Blood-Based Neurodegeneration Biomarkers - Amyloid Beta
Amyloid Beta, a peptide associated with Alzheimer's disease, is measured from fasted venous blood.
Time frame: Baseline and Week 52
Blood-Based Neurodegeneration Biomarkers - Phosphorylated Tau
Phosphorylated Tau \[p-Tau-217\], a tau protein with added phosphate groups, is measured from fasted venous blood.
Time frame: Baseline and Week 52
Blood-Based Neurodegeneration Biomarkers - Glial Fibrillary Acidic Protein (GFAP)
GFAP, a structural protein found in astrocytic cells, is measured from fasted venous blood.
Time frame: Baseline and Week 52
Hypoxia - Time Spent With SpO2<88%
Time spent with SpO2\<88% is calculated as the time spent with oxygen saturation below 88% as a percentage of time in bed, estimated using at-home oximetry.
Time frame: Hypoxia outcomes will be determined as a mean of 7-10 nights of data acquired at baseline and a mean of 7-10 nights of data acquired at 12months.
Hypoxia - Minimum SpO2
Minimum SpO2 is calculated as the minimum oxygen saturation reached during time in bed, estimated using at-home oximetry.
Time frame: Hypoxia outcomes will be determined as a mean of 7-10 nights of data acquired at baseline and a mean of 7-10 nights of data acquired at 12 month follow-up
Hypoxia - Average Desaturation
Average desaturation is calculated as the mean of all desaturation events \>=3% during time in bed, estimated using at-home oximetry.
Time frame: Hypoxia outcomes will be determined as a mean of 7-10 nights of data acquired at baseline and a mean of 7-10 nights of data acquired at 12 month follow-up
Breathing Disturbance Index (BDI)
BDI is measured by the number of breathing disturbances per hour of sleep using contactless mattress-based OSA monitors (SleepTracker-AI).
Time frame: Nightly for 12-month treatment duration.
Anthropometry - Weight (Self-Measured)
Weight (kg) - self-measured at home
Time frame: At Baseline, 3, 6, and 9 months
Plan to share: Yes — Non-identifiable IPD will be shared upon reasonable request to the Principal Investigators.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Non-identifiable IPD will become available one year after publication and will be available for ten years.
Access criteria: A copy of the non-identifiable dataset may be requested by academic collaborators not affiliated with the Woolcock Institute of Medical Research through a data request form which outlines the investigators, aims and hypotheses, data to be included, a statistical analysis plan, ethics approval, and security measures. Data can be shared with the participant or their personal health care providers regarding any potential incidental findings upon request.
Start is estimated for Oct 2026; primary completion for Dec 2028, 26 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide
Woolcock Institute of Medical Research